What Biocomposites does

Biocomposites Ltd. is an international medical device company founded in 1993 and headquartered at Keele's Science and Innovation Park in the United Kingdom. The company engineers, manufactures, and commercializes calcium compound medical devices focused on two clinical domains: bone regeneration and musculoskeletal infection management. Its portfolio spans absorbable calcium sulfate antibiotic carriers (STIMULAN), acrylic bone cements and preformed antibiotic-loaded spacers for joint revision (SYNICEM), nanocrystalline hydroxyapatite bone graft substitutes (NanoBone), biphasic tricalcium phosphate composites (genex, Allogran-R), bone cements (Subiton), and synthetic calcium composite interference screws (Biosteon, Bilok) for sports medicine applications.

The company's underlying technology is anchored by proprietary materials science, notably the DRy26 recrystallization process—a 26-step, 6-week pharmaceutical-grade calcium sulfate synthesis—and NanoBone's unsintered nanocrystalline hydroxyapatite embedded in a silica gel matrix. These are protected by an extensive patent portfolio across the US, EU, China, and Japan. STIMULAN holds regulatory distinction as the only calcium matrix antibiotic carrier certified under EU MDR for mixing with combinations of Gram-positive and Gram-negative antibiotics, sustaining elution above minimum inhibitory concentration for over 40 days.

Biocomposites operates a hybrid direct-sales and distributor go-to-market model, reaching healthcare providers in 100+ countries, with products used in over one million procedures annually. The company maintains manufacturing in Keele (UK) and Chamberet, France (via its Synimed subsidiary acquired in 2022), produces approximately one million units per year, and is privately held with growth-equity backing from TA Associates and Novo Holdings following a March 2025 investment. Biosteon products are distributed exclusively through Stryker for ACL reconstruction. The company's end customers are orthopaedic surgeons, trauma specialists, podiatrists, spine surgeons, and infection management professionals operating in hospital and surgical settings.

Name

Biocomposites

Legal name

Biocomposites Ltd.

Website

https://biocomposites.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Orthopaedic and trauma medical devices

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industries

Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle) (HLAHAEAA), Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair) (HLAHAEAF), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB)

Keywords

• Calcium compound medical devices
• Bone graft substitutes
• Antibiotic loaded cements
• Orthopaedic infection management
• Calcium sulfate carriers

Headquarters

HQ city

Keele

HQ country

United Kingdom

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sale of calcium compound medical devices including bone grafts, antibiotic carriers, bone cements, spacers, and interference screws for orthopaedic, trauma, spine, and infection management applications. Products sold through direct sales and distributor network in over 100 countries.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Biocomposites engineers, manufactures, and markets calcium compound and specialty polymer medical devices for bone regeneration and infection management. Its portfolio includes absorbable calcium sulfate antibiotic carriers (STIMULAN), acrylic bone cements and preformed antibiotic-loaded spacers (SYNICEM), nanostructured hydroxyapatite bone graft substitutes (NanoBone), biphasic and beta-tricalcium phosphate bone grafts (genex, Allogran-R), and synthetic calcium composite interference screws (Biosteon, Bilok) used in musculoskeletal infection, trauma, spine, foot and ankle, and sports medicine procedures.

Product overview

Biocomposites is an international medical device company offering a comprehensive portfolio of calcium compound and specialty polymer medical devices for bone regeneration and infection management. The portfolio includes: STIMULAN® (absorbable calcium sulfate antibiotic carriers), SYNICEM™ (bone cements, spacers, and related surgical products from subsidiary Synimed), NanoBone® (nanostructured hydroxyapatite bone graft), genex® (tricalcium phosphate bone graft), Allogran-R® (β-calcium phosphate substitute), Subiton cements, Biosteon® and Bilok® (interference screws for sports medicine). Products serve musculoskeletal infection, trauma, spine, foot and ankle, and sports injuries specialties across more than 100 countries.

Differentiator

Problem solved

Functional benefit

Brands

• STIMULAN: Truly absorbable calcium sulfate antibiotic carrier approved for use in bone and soft tissue. The only calcium matrix antibiotic carrier certified for use in bone and surrounding soft tissue, with products including Rapid Cure and Kit variants.
• SYNICEM
• NanoBone
• genex
• Allogran-R
• Subiton
• Biosteon
• Bilok

Products and services

• STIMULAN Truly absorbable calcium sulfate antibiotic carrier approved for use in bone and soft tissue for musculoskeletal infection management, including STIMULAN Rapid Cure (3cc/5cc/10cc/20cc bead kits with ~4 minute set time) and STIMULAN Kit (5cc/10cc fully injectable paste with ~8 minute set time), supported by STIMULAN Bullet Mat and Introducer accessories for hard-to-reach defects. Used by orthopaedic surgeons, infection specialists, foot and ankle surgeons, trauma surgeons, and microbiologists for osteomyelitis, periprosthetic joint infections, diabetic foot osteomyelitis, infected non-unions, and surgical site infections.
• SYNICEM Pioneering product line for infection management encompassing bone cements (SYNICEM 1, SYNICEM 1G with gentamicin, SYNICEM 3, SYNICEM 3G with gentamicin), preformed antibiotic-loaded hip, knee and shoulder spacers with gentamicin for revision procedures, antibiotic-coated intra-medullary CLOUS nails for infected diaphyseal fractures, SYNICEM VTP and SYNICEM KYP cements for vertebroplasty and kyphoplasty, SYNICEM Cranioplastie for cranial and facial reconstruction, and SYNIMIX V vacuum mixing and SERINGUE SYNICEM GUN delivery systems. Manufactured by subsidiary Synimed and distributed through Biocomposites for orthopaedic, neurosurgical, maxillofacial and plastic surgical applications in over 70 countries.
• NanoBone Next generation fully synthetic bone graft substitute consisting of nanostructured hydroxyapatite embedded in a silica gel matrix suspended in hydrogel/polymer silica carrier, with unsintered HA preserving a highly porous nanoarchitecture for bone regeneration. Offered as SBX Putty and QD formulations for orthopaedic and trauma surgeons treating bone defects with rapid absorption and reliable bone fusion.
• genex Biphasic composite bone graft substitute of beta-tricalcium phosphate and calcium sulfate hemihydrate that acts as a catalyst for bone healing, completely absorbed within 12 months leaving no foreign artifacts, with negatively charged surface chemistry and compressive strength similar to trabecular bone. Available as setting paste, ds paste, and putty formulations for orthopaedic, trauma, spine, and non-union procedures.
• Allogran-R Fully absorbable beta tri-calcium phosphate bone substitute with engineered porosity for complete absorption within 6 to 12 months, used as an osteoconductive matrix for treatment of trauma, spine, and non-unions with no risk of disease transmission.
• Subiton Cements Bone cements optimised for secure and stable fixation in joint replacement surgery, including Subiton RO with high performance mechanical properties, Subiton G with gentamicin for high-risk infection patients, and Subiton GUN and GUN G delivery variants.
• Biosteon Synthetic calcium composite interference screws using osteoconductive calcium hydroxyapatite particles in a poly-L-lactic acid (PLLA) matrix, with improved strength retention, bone-bonding potential and pH buffering, alongside the Biosteon IntraLine suture anchor for rotator cuff repairs. Designed for sports medicine surgeons treating ACL injuries and rotator cuff tears where bioresorbable implants are preferred over metal hardware. Distributed exclusively through Stryker.
• Bilok Synthetic calcium composite interference screws using beta tri-calcium phosphate particles in a poly-L-lactic acid matrix for ACL and posterior ligament reconstruction, and suture anchors for rotator cuff repairs. Indicated for sports medicine procedures where absorbable implants are preferred.

Quantifiable outcome

• STIMULAN sustains antibiotic levels above MIC for over 40 days
• +2 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Artoss GmbHcoreStrategic or Co-development Partner · 1 June 2023Acquired by Biocomposites in June 2023, Artoss GmbH was a German manufacturer of bone graft substitutes using NanoBone technology. The acquisition expanded Biocomposites' product portfolio and global distribution network with proprietary nanocrystalline hydroxyapatite and silica gel technology.
• SynimedcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2022Synimed became part of the Biocomposites Group in 2022, bringing the SYNICEM product range including bone cements, spacers, antibiotic-loaded nails, and mixing/delivery systems. Synimed manufactures products at Chamberet, France facility.
• StrykercoreChannel Partner/ Reseller/ DistributorBiosteon interference screws for ACL reconstruction and Biosteon IntraLine Suture Anchor are manufactured by Biocomposites but sold and distributed exclusively through Stryker.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Heraeus Medical: Heraeus Medical is the global leader in orthopaedic bone cements (PALACOS, COPAL) and antibiotic-loaded bone cements, directly comparable to Biocomposites' SYNICEM bone cement and STIMULAN antibiotic carrier franchise for musculoskeletal infection management.
• BONESUPPORT Holding AB: BONESUPPORT is a Swedish orthobiologics company developing CERAMENT antibiotic-loaded bone void fillers, a direct competitor to Biocomposites' STIMULAN calcium matrix antibiotic carrier for musculoskeletal infection.

Broad incumbents

• Zimmer Biomet: Zimmer Biomet is a major orthopaedic device manufacturer with overlapping bone graft, bone substitute, and joint reconstruction portfolios; comparable to Biocomposites' calcium-based bone grafts and SYNICEM spacers used in joint revision.
• DePuy Synthes (Johnson & Johnson): DePuy Synthes is the orthopaedic and trauma division of J&J MedTech, with broad bone graft substitute offerings and trauma plating/nailing systems that overlap with Biocomposites' Allogran-R, NanoBone, and SYNICEM antibiotic-loaded nail products.
• Stryker: Stryker is both Biocomposites' exclusive distribution partner for Biosteon ACL/rotator cuff screws and a broad orthopaedic and sports medicine incumbent with overlapping sports medicine and orthobiologic product lines.
• Smith+Nephew: Smith+Nephew is a global medical device company with significant orthopaedic reconstruction, sports medicine, and advanced wound management portfolios, competing in adjacent segments to Biocomposites' bone grafts and infection-management products.
• Arthrex: Arthrex is a leading privately-held sports medicine and orthopaedic soft tissue repair company; comparable to Biocomposites' Biosteon/Bilok interference screws and suture anchors for ACL and rotator cuff repair.
• Medtronic: Medtronic's Spine division offers INFUSE (rhBMP-2) and other orthobiologics used in spinal fusion and bone grafting, comparable to Biocomposites' NanoBone, genex, and Allogran-R products serving spine surgeons.

Emerging players

• Bone Solutions Inc. Bone Solutions Inc. develops Mg-based and calcium-based bone void fillers and orthobiologics (OSTEOAMP, OSTEOMATRIX), an emerging competitor with similar synthetic bone graft technology to Biocomposites' genex and NanoBone lines.
• OsteoRemedies: OsteoRemedies specializes in antibiotic-loaded calcium sulfate bone void fillers and infection management products in orthopaedics, making it a direct niche competitor to Biocomposites' STIMULAN platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/Biocomposites1
• LinkedInlinkedin.com/company/biocomposites-ltd
• Instagraminstagram.com/biocomposites1

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocomposites